Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation
Advanced Pharmaceutical Bulletin · 19.05.2026 · 16 (1) · 6-7
DOI: 10.34172/apb.46533 ↗Kurz gefasst
Leserbrief in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 10.05.2026. Verfasst von Arash Abdolmaleki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, Faculty of Advanced Technologies, University of Mohaghegh Ardabili, Namin, Iran. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Biophysics, Faculty of Advanced Technologies, University of Mohaghegh Ardabili, Namin, Iran.
- College of Nursing, University of Al-Ameed, Karbala, Iraq.
- Department of Clinical Laboratories, College of Applied Medical Sciences, University of Kerbala, Karbala, Iraq.
ORCID-Profile: Arash Abdolmaleki
Zitieren
APA
Abdolmaleki, A., Jafari Dargahlou, S., & A Ghanimi, H. (2026). Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation. Advanced Pharmaceutical Bulletin, 16(1), 6-7. https://doi.org/10.34172/apb.46533
Vancouver
Abdolmaleki A, Jafari Dargahlou S, A Ghanimi H. Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation. Advanced Pharmaceutical Bulletin. 2026;16(1):6-7. doi:10.34172/apb.46533
BibTeX
@article{Abdolmaleki2026,
author = {Abdolmaleki, Arash and Jafari Dargahlou, Sina and A Ghanimi, Hussein},
title = {Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation},
journal = {Advanced Pharmaceutical Bulletin},
year = {2026},
volume = {16},
number = {1},
pages = {6--7},
doi = {10.34172/apb.46533}
}
EUVIMED